Casper K. Nielsen MSc, PhD

Casper Kjærsgaard Nielsen is Postdoctoral Researcher at the Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, Denmark. He has been involved in research since 2019, holds a master’s degree in Human Physiology from the University of Copenhagen, and has a PhD in Basal Metabolic Research. His PhD (“Treatment of post-bariatric hypoglycaemia using dasiglucagon, a glucagon analogue in a ready-to-use formulation”) concerned new treatment options for post-bariatric hypoglycaemia, which is a well-known but poorly treated complication of bariatric surgery. Currently, he is employed at the Center for Clinical Metabolic Research, where he is responsible for a phase II clinical study ('DREAM'/ NCT05788601) involving first-in-class dapiglutide, a GLP-1/GLP-2 receptor agonist (Zealand Pharma A/S, Søborg, Denmark), for the treatment of obesity. Furthermore, he is engaged in or supervises a number of research projects, including the appetite-regulating effects of oxytocin, long-term effects of GIP infusion with and without semaglutide, anti-inflammatory effects of colchicine in people with type 1 diabetes, the effect of transcutaneous vagus nerve stimulation in people with diabetes and mechanistic studies of GIP/GLP-1/GLP-2 antagonism in total pancreatectomized and patients affected from postprandial hypotension. In addition, he referees several international journals, including the European Journal of Endocrinology (EJE).